Biofabrication of an in-vitro bone model for Gaucher disease
Source abstract
Abstract
Abstract Gaucher disease (GD), the most prevalent lysosomal disorder, is caused by GBA1 gene mutations, leading to deficiency of glucocerebrosidase, and accumulation of glycosphingolipids in cells of the mononuclear phagocyte system. While skeletal diseases are the leading cause of morbidity and reduced quality of life in GD, the pathophysiology of bone involvement is not yet fully understood, partly due to lack of relevant human model systems. In this work, we present the first 3D human model of GD using aspiration-assisted freeform bioprinting, which enables a platform tool with a potential for decoding the cellular basis of the developmental bone abnormalities in GD. In this regard, human bone marrow-derived mesenchymal stem cells (obtained commercially) and peripheral blood mononuclear cells derived from a cohort of GD patients, at different severities, were co-cultured to form spheroids and differentiated into osteoblast and osteoclast lineages, respectively. Co-differentiated spheroids were then 3D bioprinted into rectangular tissue patches as a bone tissue model for GD. The results revealed positive alkaline phosphatase (ALP) and tartrate-resistant ALP activities, with multi-nucleated cells demonstrating the efficacy of the model, corroborating with gene expression studies. There were no significant changes in differentiation to osteogenic cells but pronounced morphological deformities in spheroid formation, more evident in the ‘severe’ cohort, were observed. Overall, the presented GD model has the potential to be adapted to personalized medicine not only for understanding the GD pathophysiology but also for personalized drug screening and development.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: 3D Printing in Biomedical Research · Lysosomal Storage Disorders Research · Cell Image Analysis Techniques
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (55)
Show source-provided references
1. Immunological cells and functions in Gaucher disease10.1615/CritRevOncog.2013004503 ↗
2. Therapeutic approaches to bone pathology in Gaucher disease: past, present and future10.1016/j.ymgme.2011.08.004 ↗
3. Gaucheromas: when macrophages promote tumor formation and dissemination10.1016/j.bcmd.2016.10.018 ↗
4. Pathogenesis of bone alterations in Gaucher disease: the role of immune system10.1155/2015/192761 ↗
5. Clinical manifestations and management of Gaucher disease10.11138/ccmbm/2015.12.2.157 ↗
6. Characterization of neuronopathic Gaucher disease among ethnic poles10.1097/01.gim.0000196443.42899.25 ↗
7. Macrophages: their emerging roles in bone10.1002/jbmr.2735 ↗
8. Regulation of osteoclast differentiation by cytokine networks10.4110/in.2018.18.e8 ↗
9. Editorial: Inflammatory osteoclasts: a different breed of bone eaters?10.1002/art.39835 ↗
10. Bone biomarker for the clinical assessment of osteoporosis: recent developments and future perspectives10.1186/s40364-017-0097-4 ↗
11. The role of dickkopf-1 in bone development, homeostasis, and disease10.1182/blood-2008-03-145169 ↗
12. Biology of the RANKL-RANK-OPG system in immunity, bone, and beyond10.3389/fimmu.2014.00511 ↗
13. Functions of RANKL/RANK/OPG in bone modeling and remodeling10.1016/j.abb.2008.03.018 ↗
14. TRAP5b and RANKL/OPG predict bone pathology in patients with Gaucher disease10.3390/jcm10102217 ↗
15. Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption10.1359/jbmr.2000.15.7.1337 ↗
16. Value of glucosylsphingosine (Lyso-Gb1) as a biomarker in Gaucher disease: a systematic literature review10.3390/ijms21197159 ↗
17. Wnt signaling pathway inhibitors, sclerostin and DKK-1, correlate with pain and bone pathology in patients with Gaucher disease10.3389/fendo.2022.1029130 ↗
18. Anti-sclerostin antibodies in osteoporosis and other bone diseases10.3390/jcm9113439 ↗
19. Drug discovery of DKK1 inhibitors10.3389/fphar.2022.847387 ↗
20. Osteoporosis treatment with anti-sclerostin antibodies—mechanisms of action and clinical application10.3390/jcm10040787 ↗
21. Macrophage models of Gaucher disease for evaluating disease pathogenesis and candidate drugs10.1126/scitranslmed.3008659 ↗
22. Induction of osteoclastogenesis in an in vitro model of Gaucher disease is mediated by T cells via TNF-α10.1016/j.gene.2012.07.071 ↗
23. Gaucher disease IPSC-derived osteoblasts have developmental and lysosomal defects that impair bone matrix deposition10.1093/hmg/ddx442 ↗
24. Enhanced osteogenic protein expression on human osteoblast-osteoclast co-culture system using doped hydroxyapatite plasma coatings for orthopedic and dental applications10.1016/j.mtcomm.2019.05.010 ↗
25. In vitro characterizations of Si4+ and Zn2+ doped plasma sprayed hydroxyapatite coatings using osteoblast and osteoclast coculture10.1021/acsbiomaterials.8b01553 ↗
26. Osteoclast-mediated resorption on additively manufactured porous metal and plasma-sprayed HA-coated Ti implants10.1557/s43578-021-00278-3 ↗
27. Aspiration-assisted freeform bioprinting of mesenchymal stem cell spheroids within alginate microgels10.1088/1758-5090/ac4dd8 ↗
28. Aspiration-assisted bioprinting for precise positioning of biologics10.1126/sciadv.aaw5111 ↗
29. Mesenchymal stem cells: amazing remedies for bone and cartilage defects10.1186/s13287-020-02001-1 ↗
30. Mesenchymal stem cells: cell fate decision to osteoblast or adipocyte and application in osteoporosis treatment10.3390/ijms19020360 ↗
31. Osteoclasts have multiple roles in bone in addition to bone resorption10.1615/CritRevEukarGeneExpr.v19.i3.10 ↗
32. THP-1 cells as a model for human monocytes10.21037/atm.2016.08.53 ↗
33. Lipopolysaccharide-mediated cell activation without rapid mobilization of cytosolic free calcium10.1016/j.molimm.2004.05.003 ↗
34. Utilization of E-cadherin by monocytes from tumour cells plays key roles in the progression of bone invasion by oral squamous cell carcinoma10.3892/or.2017.5749 ↗
35. Dynamic analysis of hepatoma spheroid formation: roles of E-cadherin and Β1-integrin10.1007/s00441-005-0148-2 ↗
36. Gaucher’s disease: a rare case, diagnosed by fine needle aspiration cytology10.7860/JCDR/2016/16895.7498 ↗
37. Enhanced osteogenesis of human mesenchymal stem cells by periodic heat shock in self-assembling peptide hydrogel10.1089/ten.tea.2012.0070 ↗
38. In vitro osteoblastic differentiation of mesenchymal stem cells generates cell layers with distinct properties10.1186/s13287-018-0942-x ↗
39. Aspiration-assisted freeform bioprinting of pre-fabricated tissue spheroids in a yield-stress gel10.1038/s42005-020-00449-4 ↗
40. Bone marrow microenvironment in an in vitro model of Gaucher disease: consequences of glucocerebrosidase deficiency10.1089/scd.2011.0365 ↗
41. Bone acid phosphatase: tartrate-resistant acid phosphatase as a marker of osteoclast function10.1007/BF02411252 ↗
42. Bone events and evolution of biologic markers in Gaucher disease before and during treatment10.1186/ar3111 ↗
43. Current advances and future perspectives in extrusion-based bioprinting10.1016/j.biomaterials.2015.10.076 ↗
44. 3D bioprinting of cell‐laden hydrogels for improved biological functionality10.1002/adma.202103691 ↗
45. Hydrogel-based 3D bioprinting: a comprehensive review on cell-laden hydrogels, bioink formulations, and future perspectives10.1016/j.apmt.2019.100479 ↗
46. Microfabrication of scaffold-free tissue strands for three-dimensional tissue engineering10.1088/1758-5090/7/3/031002 ↗
47. Scaffold-based or scaffold-free bioprinting: competing or complementing approaches?10.1115/1.4030414 ↗
48. Scaffold-free cell-based tissue engineering therapies: advances, shortfalls and forecast10.1038/s41536-021-00133-3 ↗
49. Aspiration-assisted bioprinting of co-cultured osteogenic spheroids for bone tissue engineering10.1088/1758-5090/abc1bf ↗
50. Inflammation, ageing, and bone regeneration10.1016/j.jot.2017.04.002 ↗
51. Cytokine interactions in mesenchymal stem cells from cord blood10.1016/j.cyto.2005.11.003 ↗
52. Role of OSCAR signaling in osteoclastogenesis and bone disease10.3389/fcell.2021.641162 ↗
53. Impact of sphingolipids on osteoblast and osteoclast activity in Gaucher disease10.1016/j.ymgme.2018.06.007 ↗
54. In vivo inactivation of glycosidases by conduritol B epoxide and cyclophellitol as revealed by activity‐based protein profiling10.1111/febs.14744 ↗
55. Animal models for Gaucher disease research10.1242/dmm.008185 ↗